Navigation Links
AstraZeneca's Zactima to Earn Almost Five Percent Patient Share in the Treatment of Non-Small-Cell Lung Cancer by 2016
Date:3/20/2008

Physicians Indicate that Most Promising Emerging Therapies Will Not Match the Current Gold-Standard Avastin/Taxol/Paraplatin Regimen's Efficacy,

According to a New Report from Decision Resources

WALTHAM, Mass., March 20 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the emerging drug Zactima from AstraZeneca will earn 4.7 percent patient share in the treatment of non-small-cell lung cancer (NSCLC) by 2016. Surveyed oncologists indicate that they would prescribe Zactima to 30 percent of their patients with advanced non-small-cell lung cancer. Also, 38 percent of the physicians surveyed indicate they will use Zactima as an adjunct to current therapy rather than as a replacement. Zactima is forecasted to launch in 2008 in the United States and Europe and in 2010 in Japan.

According to the new report entitled Non-Small-Cell Lung Cancer (Advanced): Current Gold-Standard Therapy Continues to Be Most Efficacious; physicians indicate that the most promising emerging therapies for the treatment of non-small-cell lung cancer will not match the current gold- standard regimen comprising Roche/Genentech/Chugai's Avastin, Bristol-Myers Squibb's Taxol, and Bristol-Myers Squibb's Paraplatin.

"Although some therapies in development for advanced NSCLC hold promise, most have efficacy, safety and tolerability, and/or delivery features that merit inferior scores compared with the Avastin/Taxol/Paraplatin regimen," said Andrew Merron, Ph.D., analyst at Decision Resources. "A therapy's effect on overall survival is the attribute that most influences prescribing decisions in advanced non-small-cell lung cancer. Data and the opinions of interviewed thought leaders indicate that Avastin/Taxol/Paraplatin has advantages over the sales-leading combination of Sanofi-Aventis's Taxotere and Bristol-Myers Squibb's Platinol-AQ on overall survival."

About the Report

Non-Small-Cell Lung Cancer (Advanced): Current Gold-Standard Therapy Continues to Be Most Efficacious is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price- per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC)
2. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
3. VAP Cholesterol Test From Atherotech Covers 90 Percent of Arizona Insured
4. Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History
5. The Center for Molecular Medicine Doubles Lab Staff, Expands Lab Space by 100 Percent
6. LUMEDX Updates Real-Time Patient and Resource Scheduler for Healthcare Systems
7. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
8. 960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotechs Novel 5-FU Central Venous Catheter
9. C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study
10. First Patient Enrolled in SONIC I Registry of OmniSonics Medical Technologies OmniWave(TM) Endovascular System
11. Apieron, Inc. Announces FDA Clearance of the Insight(TM) eNO System to Assist Physicians with Patient Asthma Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is pleased to announce the launch of their brand, UP4™ Probiotics, into Target ... over 35 years, is proud to add Target to its list of well-respected ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... HOUSTON , June 23, 2016 ... agreement with the Cy-Fair Sports Association to serve ... of the agreement, Houston Methodist Willowbrook will provide ... education and connectivity with association coaches, volunteers, athletes ... partner with the Cy-Fair Sports Association and to ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) ... precise treatments and faster cures for prostate cancer. Members of the Class of ... 15 countries. Read More About the Class of 2016 ... ... ...
Breaking Biology Technology:
(Date:6/2/2016)... 2016 Perimeter Surveillance & Detection ... Physical Infrastructure, Support & Other Service  The ... offers comprehensive analysis of the global Border Security ... revenues of $17.98 billion in 2016. Now: ... leader in software and hardware technologies for advanced video ...
(Date:5/24/2016)... care by providing unparalleled technology to leaders of the medical imaging industry.  As such, ... to the range of products distributed by Ampronix. Photo - http://photos.prnewswire.com/prnh/20160524/371420 ... ... ... With ...
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
Breaking Biology News(10 mins):